Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced the completion of its Phase 1 clinical trial of TQS-168, a small molecule modulator of PGC-1a in development for the treatment of...
